+5 more
Haldid, Onsolis, Instanyl, Abstral, Lazanda+1 more
Opioid systemmorphine, heroin, oxycodone +6 moremorphine, heroin, oxycodone, hydrocodone, methadone, codeine, hydromorphone, oxymorphone, buprenorphine show less
Fentanyl
Fentanyl is a synthetic opioid of the anilidopiperidine class. It is 80–100 times more potent than morphine at equivalent clinical doses.[1] Fentanyl is a full agonist at µ-opioid receptors, producing its effects by suppressing pain signaling and depressing respiratory drive.
+5 more
Haldid, Onsolis, Instanyl, Abstral, Lazanda+1 more
Opioid systemmorphine, heroin, oxycodone +6 moremorphine, heroin, oxycodone, hydrocodone, methadone, codeine, hydromorphone, oxymorphone, buprenorphine show less
First synthesized in 1960 by Paul Janssen,[2] fentanyl became a cornerstone of surgical anesthesia and the most versatile clinical opioid. Illicitly manufactured forms entered the drug supply in the early 2010s, driving a catastrophic rise in overdose deaths.[3] It is now the leading cause of overdose death in the United States.
Subjective effects include profound pain suppression, euphoria, heavy sedation, and a warm dissolution of anxiety and distress.[4] The experience is defined by what it removes — discomfort disappears and the body settles into a weighted, quiet calm. Nausea, respiratory depression, and severe constipation are characteristic unwanted effects.
Fentanyl produces rapid physical dependence,[5] and the gap between an active dose and a fatal dose is among the narrowest of any commonly used drug.[1] Tolerance to pain relief builds faster than tolerance to breathing suppression, so dose escalation narrows the margin of safety.[6] It is one of the most studied opioids, with clinical data spanning six decades.
History[edit]
Discovery
Fentanyl was synthesized in 1960 by Belgian chemist Paul Janssen,[2][7] designed as a more selective opioid for surgical anesthesia. It was placed under Schedule I of the UN Single Convention on Narcotic Drugs in 1964[1] and classified as DEA Schedule II in 1970.[8]
Clinical Adoption
Fentanyl entered US anesthesia practice in the early 1970s,[2][9] transforming cardiac surgery by providing deep pain suppression with stable blood pressure. It became available across multiple delivery forms — injectable, transdermal patch, and oral lozenge — establishing it as the most versatile clinical opioid.
The Illicit Fentanyl Crisis
From 2013, illicitly manufactured fentanyl drove catastrophic overdose death rates in North America — a 1,040% increase in synthetic opioid deaths from 2013 to 2019.[3] Fentanyl began appearing in cocaine and methamphetamine,[10] and xylazine emerged as a common adulterant,[11] expanding the risk to people not intentionally using opioids.
Chemistry[edit]
Structural Class
Fentanyl belongs to the anilidopiperidine class of synthetic opioids — a scaffold designed by Paul Janssen to optimize opioid receptor selectivity.[2] Its molecular formula is C₂₂H₂₈N₂O.
The compound is highly fat-soluble (logP 4.05),[12][7] which drives its rapid entry into the brain. Small structural changes to the scaffold generate analogs with dramatically different potencies.[1]
Pharmacology[edit]
Mechanism of Action
Fentanyl is a full agonist at µ-opioid receptors,[13] meaning it fully activates opioid signaling. This suppresses pain transmission, dampens neurotransmitter activity, and depresses breathing — all through the same receptor pathway.
Molecular research shows fentanyl can occupy a deep pocket inside the opioid receptor,[14][15] holding on longer than most opioids. This extended binding may explain why fentanyl overdoses can be harder to reverse with naloxone.
Pharmacokinetics
Fentanyl's fat solubility lets it cross the blood-brain barrier within minutes.[7] The liver breaks it down via the CYP3A4 enzyme,[16] and clearance depends on liver blood flow.[17] Large doses accumulate in body fat and cause renewed respiratory depression hours after the last dose.[18]
Neuroscience[edit]
Where It Acts
Fentanyl activates opioid receptors across three brain regions. In the mesolimbic pathway, it triggers a surge of dopamine — the speed of this effect amplifies its addictive pull.[7] In the descending pain system, it suppresses pain signals before they reach consciousness.
In the brainstem, fentanyl slows breathing and blunts the body's normal alarm response to rising carbon dioxide.[6][19] This is the mechanism behind overdose death: breathing slows and stops without the person noticing.
Why It Matters
Chronic use rewires the brain's reward and stress systems, establishing a baseline that requires the drug's presence to function normally.[20] Withdrawal is the unmasking of this process — dysphoria, pain, and physical distress emerge as the brain overcorrects.[21]
Individual vulnerability to respiratory depression varies considerably: repeated exposure produced adaptive tolerance in 77% of mice but no adaptation in 23%.[6] Whether fentanyl's deep binding mode[14] explains why some overdoses resist naloxone has not been confirmed in living subjects. No neuroimaging study specific to fentanyl has been published, leaving long-term cognitive consequences uncharacterized.
Subjective Effects[edit]
Fentanyl's experience is defined by erasure. Pain disappears. Anxiety dissolves. The body settles into a weighted warmth, and thought narrows to a quiet drift. At lower doses cognitive clarity persists alongside that warmth; at higher doses, consciousness narrows further — external stimuli fade and the body feels immovably heavy.
Compared to morphine and heroin, fentanyl is frequently described as "cleaner" — less histamine-driven itching and flushing — but shorter-lived. It lacks the deep physical warmth that characterizes morphine at equivalent analgesic effect, reflecting its narrower receptor profile.
Synthesized by Paul Janssen in 1960 as part of a search for improved surgical anesthetics,[2] fentanyl became a cornerstone of cardiac anesthesia by combining profound analgesia with hemodynamic stability. Illicitly manufactured forms entered unregulated drug markets in the early 2010s, driving a 1,040% increase in synthetic opioid overdose deaths from 2013 to 2019.[3] It is now the single leading cause of overdose death in the United States.
Subjective effects include profound analgesia, euphoria, sedation, and anxiolysis.[4] The experience is one of erasure — physical pain and emotional distress dissolve into an undifferentiated wave of warmth and heavy calm in which the body feels weighted and mental activity narrows to a quiet drift. Nausea, respiratory slowing, and severe constipation are characteristic unsought effects.
Fentanyl produces rapid physical dependence,[5] and the margin between an effective and fatal dose is measured in micrograms[1] — among the narrowest of any widely used opioid. Tolerance to analgesia develops faster than tolerance to respiratory depression,[6] so dose escalation progressively narrows the safety margin; in unregulated supply, potency varies unpredictably between doses. Six decades of clinical and pharmacological data underpin the current understanding of fentanyl.
History[edit]
Discovery
Fentanyl was synthesized in 1960 by Belgian chemist Paul Janssen at Janssen Pharmaceutica during systematic exploration of synthetic opioid structure-activity relationships.[2][7] Janssen designed the anilidopiperidine scaffold specifically to achieve high µ-opioid receptor selectivity — a design choice that "laid the foundation for a better understanding of the structure-activity relationships of narcotic analgesics".[2] The compound was placed under Schedule I of the UN Single Convention on Narcotic Drugs in 1964[1] and subsequently classified as DEA Schedule II under the US Controlled Substances Act of 1970.[8]
Clinical Adoption
Fentanyl entered US clinical anesthesia in the early 1970s,[2][9] where high-dose protocols (50–100 μg/kg) transformed cardiac surgery by providing profound analgesia with minimal hemodynamic disturbance — a significant advantage over morphine, which produced greater cardiovascular instability.[2] Commercial preparations followed across multiple routes of administration: Sublimaze (injectable), Duragesic (transdermal patch), and Actiq (oral transmucosal lozenge), establishing fentanyl as the most versatile opioid analgesic in clinical use.
The Illicit Fentanyl Crisis
From 2013 onward, illicitly manufactured fentanyl drove a catastrophic surge in overdose mortality across North America. Synthetic opioid-involved death rates increased 1,040% from 2013 to 2019,[3] and by 2017, opioids were implicated in 47,600 of 70,237 total drug overdose deaths (67.8%).[10]
The crisis deepened as fentanyl analogs proliferated, xylazine appeared as an increasingly common adulterant,[11] and contamination spread beyond opioid supplies into stimulant markets — drug checking services began detecting fentanyl in methamphetamine and cocaine samples.[12] The DEA issued a temporary class-wide Schedule I order for fentanyl-related substances in February 2018, subsequently extended through September 2025.[8]
Chemistry[edit]
Structural Class
Fentanyl belongs to the anilidopiperidine class of synthetic opioids. The parent scaffold consists of a piperidine ring bearing a phenethyl substituent on the nitrogen and an N-phenylpropanamide group at the 4-position — an architecture designed by Paul Janssen to optimize µ-opioid receptor selectivity.[2]
Structural modifications at the piperidine ring, acyl chain, and aniline nitrogen have generated a large family of analogs with widely varying potencies. Cis(+)-3-methylfentanyl, for instance, is 6,684 times more potent than morphine in animal studies.[1]
Molecular Properties
| Molecular formula | C₂₂H₂₈N₂O |
| Molecular weight | 336.5 g/mol |
The molecule contains two aromatic rings (aniline phenyl and phenethyl phenyl), a piperidine heterocycle, and a propanamide carbonyl group. The carbonyl oxygen serves as a hydrogen bond acceptor critical for receptor engagement. High lipophilicity (logP 4.05)[13] accounts for fentanyl's rapid transit across biological membranes, including the blood-brain barrier.[7]
Stereochemistry
Fentanyl possesses one chirality center at C-4 of the piperidine ring and is marketed as a racemic mixture. Stereochemistry becomes pharmacologically critical in analogs with additional chiral centers — the extreme potency of cis(+)-3-methylfentanyl (6,684× morphine) is stereospecific.[1]
Physical Properties
| Appearance | White granular or crystalline powder |
| Melting point | 83–84°C |
| Water solubility | 0.20 mg/mL (25°C) |
| logP | 4.05 |
| pKa | 8.43 (piperidine nitrogen) |
Pharmacology[edit]
Mechanism of Action
Fentanyl is a full agonist at the µ-opioid receptor (μ-opioid). Binding activates inhibitory G-protein signaling, which suppresses neuronal excitability by opening potassium channels and closing calcium channels. The net result is reduced pain transmission, suppressed neurotransmitter release, and depressed respiratory drive.
Fentanyl binds MOR with high affinity and ranks among the highest-efficacy opioid agonists tested in vitro.[14] It shows substantially weaker activity at δ-opioid and κ-opioid receptors, making its pharmacology almost entirely MOR-mediated.
Molecular simulation reveals that fentanyl engages MOR through two distinct binding configurations.[15] Beyond the canonical binding mode shared with other opioids, fentanyl adopts a secondary "deep pocket" position that extends its receptor residence time to approximately 38 seconds.[16] This deep binding mode may contribute to the difficulty of displacing fentanyl with naloxone during overdose reversal.
A negative allosteric modulator site on MOR's outer surface enhances naloxone binding and cooperatively inhibits fentanyl signaling,[17] providing a structural basis for next-generation reversal strategies.
Pharmacokinetics
Fentanyl's high lipophilicity enables rapid crossing of the blood-brain barrier, with a blood-to-brain transfer half-life of 4.7–6.6 minutes.[7] This accounts for the near-immediate onset of effects after intravenous injection and the rapid onset via insufflation or smoking.
The liver metabolizes fentanyl primarily through CYP3A4 to the inactive metabolite norfentanyl.[18] Fentanyl is classified as a high-extraction hepatic drug, meaning clearance depends more on liver blood flow than on enzyme activity.[19] This distinguishes it pharmacokinetically from many other opioids: CYP3A4 inhibitors produce more modest exposure increases for fentanyl than for low-extraction opioids, though the narrow therapeutic margin still makes such interactions clinically significant.
A single intravenous dose produces effects lasting 30–60 minutes due to redistribution from the brain into peripheral tissues (muscle, fat). Multiple or large doses overwhelm this redistribution mechanism, causing drug accumulation and prolonged respiratory depression — including secondary peaks hours after the last dose.[20]
Neuroscience[edit]
Where It Acts
Fentanyl's effects arise from µ-opioid receptor activation across three principal brain systems. In the mesolimbic mesolimbic pathway, μ-opioid activation in the ventral tegmental area disinhibits dopamine neurons, producing a surge of dopamine in the nucleus accumbens that underlies euphoria and reinforcement. Fentanyl's rapid brain entry (4.7–6.6 minutes to equilibrium[7]) amplifies this signal — faster onset produces stronger subjective reward and greater addiction liability.
In the descending pain system, MOR activation in the periaqueductal gray suppresses pain signals at the spinal cord, producing the profound analgesia that defines the opioid experience. In the brainstem, MOR agonism at the preBötzinger complex (the brain's breathing rhythm generator) reduces respiratory rate and depth,[6] while suppression of the retrotrapezoid nucleus blunts the body's response to rising CO₂ levels.[21]
Why It Matters
Chronic fentanyl use drives allostatic dysregulation of the brain's reward and stress systems. Compensatory upregulation of cellular stress signaling[22] and recruitment of anti-reward circuits establish a new baseline in which normal functioning requires the drug's presence. Withdrawal represents the unmasking of this opponent process — the brain's overshoot produces dysphoria, pain hypersensitivity, and autonomic hyperactivity. Escalating self-administration and withdrawal behavior have been confirmed in animal models.[23]
Individual vulnerability to fentanyl's respiratory effects varies substantially: repeated exposure produced adaptive tolerance in 77% of mice but no adaptation in 23%.[6] What determines whether a person develops tolerance to respiratory depression — genetics, epigenetics, or prior exposure history — remains unknown.
Subjective Effects[edit]
Fentanyl's subjective character centers on the dissolution of pain and distress into heavy, warm sedation. At lower doses the experience retains cognitive clarity alongside analgesia and mood elevation; at higher doses, consciousness narrows to a quiet drift in which external stimuli lose relevance and the body feels profoundly weighted. Route of administration strongly shapes the experience — intravenous and insufflated routes produce a rapid, intense onset that amplifies euphoria and reinforcement, while transdermal and sublingual routes distribute the same pharmacology across a longer, blunter arc. Prior opioid exposure modulates the profile substantially: an opioid-naïve individual encounters more nausea, sedation, and respiratory depression alongside euphoria than a tolerant user at the same dose.
Compared to morphine and heroin, fentanyl is frequently described as "cleaner" but shorter-lived, with less histamine-mediated itching and flushing. The experience lacks the warmth and body-heaviness that characterize morphine at equivalent analgesic effect, reflecting fentanyl's narrower receptor profile. Among other anilidopiperidines, fentanyl occupies a middle position — longer and more reinforcing than remifentanil, less potent but more widely encountered than sufentanil.
Effect Grid
Common doses produce the characteristic opioid experience: pronounced cognitive euphoria, significant anxiety suppression, strong pain suppression, and a pervasive warmth that radiates through the body. Tactile euphoria — a pleasant tingling or glowing sensation across the skin — becomes prominent. Sedation deepens, and the individual may drift between wakefulness and a dream-like nodding state.
Pupil constriction is marked. Respiratory depression becomes clinically meaningful — breathing rate and depth are noticeably reduced. Nausea and vomiting may occur, particularly in opioid-naive users. Constipation, excessive sweating, and urinary retention are common. Sexual arousal suppression is typical.
The compulsive redosing urge may emerge at this range, particularly with short-acting routes of administration. Cognitive processing slows, and the individual is functionally impaired for the duration.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Constipation · Spontaneous body sensations · Bodily heaviness · Body high · Tactile euphoria · Sexual arousal suppression · Muscle relaxation · Nausea · Physical fatigue · Excessive sweating · Appetite suppression · Dizziness · Abnormal heartbeat · Dry mouth · Tingling / electric sensations · Vomiting · Pain enhancement · Temperature dysregulation · Yawning · Involuntary body movements · Nystagmus (eye wobbles) · Muscle tension · Bodily dissociation
Body high · Tactile euphoria · Sexual arousal suppression · Muscle relaxation · Nausea · Physical fatigue · Excessive sweating · Appetite suppression · Dizziness · Dry mouth · Tingling / electric sensations · Vomiting · Pain enhancement · Temperature dysregulation · Yawning · Involuntary body movements · Nystagmus (eye wobbles) · Muscle tension · Bodily dissociation
Focus suppression · Analysis suppression · Information processing suppression · Thought deceleration · Confusion · Memory suppression · Motivation suppression · Memory fragmentation · Thought disorganization · Delusions of sobriety · Amnesia · Delirium
Thought deceleration · Confusion · Memory suppression · Motivation suppression · Memory fragmentation · Thought disorganization · Amnesia · Delirium
Anxiety · Dysphoria
Social disconnection · Depersonalization · Derealization · Cognitive disconnection
Timeline
Rapid absorption through nasal mucosa produces first alerts within 5-15 minutes. Intranasal bioavailability is 89%, making this the most efficient non-injectable route.
Effects build quickly to near-peak intensity. Warmth, euphoria, pupil constriction, and the onset of respiratory depression develop within minutes of first alerts.
Peak plasma concentration reached at approximately 12-21 minutes post-insufflation. Maximum euphoria, sedation, and respiratory depression. Tmax significantly faster than sublingual.
Effects diminish as fentanyl redistributes from brain to peripheral compartments. Sedation often outlasts euphoria.
Return toward baseline over 30-45 minutes. Residual miosis, constipation, and mild cognitive slowing persist. Compulsive redosing urge may intensify as effects wane.
Subtle residual effects including constipation, mild sedation, and reduced appetite persist for hours.
⚠ Do not drive or operate machinery for at least 12 hours after insufflation, as psychomotor impairment may outlast subjective effects.
Safety[edit]
- Acute toxicity
- Critical
- Chronic toxicity
- High
- Withdrawal
- Severe
- Tolerance buildup
- rapid
- Tolerance reset
- 14 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- morphine · heroin · oxycodone
Toxicity
Acute Toxicity
Fentanyl kills by suppressing breathing.[6][19] Opioid receptor activation in the brainstem reduces both breathing rate and depth, and blunts the body's carbon dioxide alarm. Death follows from progressive oxygen deprivation.
The gap between a therapeutic and a fatal blood concentration can be as little as 3.5 to 7 times[1] — critically narrow for a substance with unpredictable potency in unregulated supply.
Wooden Chest Syndrome
Wooden chest syndrome — high doses causing the chest wall and abdomen to seize up, making breathing mechanically impossible[22][23] — is a risk with illicit fentanyl. The mechanism may not involve opioid receptors,[9] which is why naloxone alone sometimes cannot reverse it.
Delayed Re-narcotization
Large or repeated doses cause fentanyl to accumulate in muscle and fat. Hours later, stored drug re-enters the bloodstream and produces a second wave of respiratory depression.[18] A person who appears recovered can deteriorate without any additional drug exposure.
Xylazine Combination Toxicity
Xylazine — an animal tranquilizer increasingly found mixed with illicit fentanyl[11] — adds its own suppression of breathing and heart function.[24] Naloxone reverses the fentanyl component but has no effect on xylazine. Necrotic skin wounds at injection sites are a hallmark of xylazine-adulterated supply.
Epidemiology
Synthetic opioid death rates in the United States increased 1,040% from 2013 to 2019.[3] Fentanyl contamination of cocaine and methamphetamine[10] expands the at-risk population beyond people who intentionally use opioids.
Psychological Risks
Fentanyl's addiction liability is high. Rapid brain entry and full opioid receptor activation produce strong euphoria and anxiety relief, driving compulsive redosing.[7] Physical and psychological dependence reinforce each other.
Chronic opioid use is associated with deficits in attention, memory, and executive function,citation needed though no study specific to fentanyl has characterized these effects.
Tolerance & Dependence
Tolerance develops as the brain desensitizes and withdraws opioid receptors,[5] while compensatory changes establish a new baseline requiring the drug's presence.[20] Fentanyl may produce faster tolerance development than morphine.[25]
Critically, tolerance to pain suppression appears to develop faster than tolerance to breathing suppression[6] — so dose escalation to maintain effect progressively narrows the margin of safety. Cross-tolerance extends to all µ-opioid agonists: Morphine, heroin, oxycodone, hydrocodone, and methadone.
Physical dependence develops rapidly. Withdrawal produces dysphoria, muscle pain, sweating, nausea, vomiting, diarrhea, and autonomic hyperactivity.citation needed[21]
Drug Interactions
Depressants (benzodiazepines, alcohol, GHB/GBL, tramadol, Heroin) add to fentanyl's breathing suppression — this combination is the leading cause of fatal opioid overdose. Gabapentinoids (gabapentin, pregabalin) both increase fentanyl's potency and impair naloxone's ability to reverse an overdose[26] — a uniquely hazardous double effect.
CYP3A4 inhibitors such as ketoconazole[27] and ritonavir[28] reduce fentanyl breakdown and raise exposure. Xylazine adds depression that naloxone cannot reverse.[24] Fentanyl overdoses typically require higher or repeated naloxone doses compared to heroin;[29] nalmefene offers a longer-acting reversal alternative.[30]
Contraindications
8 knownFentanyl is absolutely contraindicated with known allergy to anilidopiperidine opioids, severe unmonitored breathing difficulties, and bowel obstruction. Liver impairment reduces clearance because fentanyl elimination depends on liver blood flow.[17] Concurrent CYP3A4 inhibitors require dose reduction.
Benzodiazepines, alcohol, and other depressants are a strong relative contraindication due to additive breathing suppression. Gabapentinoid co-use warrants specific caution — it amplifies fentanyl and impairs naloxone reversal.[26] Elderly patients and those with kidney impairment require dose adjustment due to extended elimination.[18]
Harm Reduction[edit]
Forms & Identification
The core challenge with illicit fentanyl is that potency is invisible. Pharmaceutical fentanyl comes in precisely dosed forms — patches, lozenges, injectable solutions. Illicitly manufactured fentanyl is distributed as powder, pressed pills, or liquid applied to blotter or nasal spray.
Pressed pills often mimic pharmaceutical oxycodone (M30 tablets) or benzodiazepines in appearance, but contain wildly variable fentanyl concentrations, including fatal doses in a single pill. There is no way to determine dose from appearance.
Fentanyl test strips detect the presence of fentanyl in a sample but cannot determine concentration. A positive confirms fentanyl is present; a negative does not guarantee safety, as distribution within a batch can be uneven.
Guidelines
- Test every dose with fentanyl test strips before use
- Start with a fraction of the intended dose ("go low, go slow"), especially from a new batch or after any break in use — tolerance drops rapidly
- Never use alone; ensure someone present has naloxone and knows how to use it
- Have at least two doses of naloxone (Narcan) immediately accessible, not stored in another room
- Avoid mixing with benzodiazepines, alcohol, gabapentinoids, or other depressants — these combinations are the most common cause of fatal overdose
- If smoking or snorting, take a small test amount and wait before redosing
- If injecting, use slowly; rapid injection increases wooden chest syndrome risk
- After any tolerance break (days in hospital, jail, detox, or simply not using for 3+ days), assume your previous dose is now potentially fatal
Set & Setting
Fentanyl's acute lethal risk makes environment and company safety-critical, not a matter of preference. Never use alone — breathing can fail within minutes, and an unconscious person cannot self-administer naloxone. A sober companion with naloxone access and knowledge of rescue breathing is the single most effective risk reduction measure.
Avoid locations where emergency services cannot reach. Do not use in water — loss of consciousness means drowning.
Aftercare & integration. After an overdose reversal, medical monitoring is the priority. Naloxone wears off faster than fentanyl, and respiratory depression can return hours later.[18] Emergency department observation for at least 2–4 hours after the last naloxone dose is standard.
Naloxone reversal triggers acute withdrawal in dependent individuals — intense dysphoria, pain, nausea, and agitation. This is medically expected and not dangerous, but the discomfort drives many people to leave care and use again immediately, creating a second overdose window.
Regular fentanyl use produces cumulative harm: sleep disruption, constipation, hormonal changes, and progressive sociability suppression. Recognizing the pattern of needing more to feel the same effect, or using to avoid withdrawal rather than for effect, is the first step toward seeking support.
Recovery & Support
Fentanyl dependence is treatable. Medications for opioid use disorder (MOUD) — buprenorphine (Suboxone, Sublocade) and methadone — reduce overdose death by 50% or more. These stabilize brain chemistry and eliminate withdrawal — they are not simply substituting one drug for another.
Buprenorphine induction from fentanyl requires careful timing. Starting too early triggers precipitated withdrawal — sudden, severe withdrawal that emerges immediately. Low-dose induction protocols have been developed specifically to address this risk.
Methadone programs provide supervised daily dosing. Some people with fentanyl dependence require higher methadone doses than were typical for heroin dependence.
Peer support resources include SMART Recovery, Narcotics Anonymous, and harm reduction organizations that offer low-barrier support regardless of readiness to stop using. The National Drug Helpline (1-844-289-0879) and SAMHSA Helpline (1-800-662-4357) provide free referrals.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Slow or stopped breathing, blue or gray lips and fingertips, gurgling or snoring sounds from an unconscious person, pinpoint pupils with unresponsiveness, rigid chest or abdomen (wooden chest syndrome). An opioid overdose can look like someone "nodding off" — the difference is that they cannot be woken by loud voice or sternal rub.
Immediate steps:
- 1. Call emergency services immediately
- 2. Administer naloxone: intranasal (4 mg spray in one nostril) or intramuscular injection
- 3. If no response after 2–3 minutes, administer a second dose of naloxone
- 4. Begin rescue breathing if the person is not breathing: tilt head back, lift chin, give one breath every 5 seconds
- 5. Place in recovery position (on their side) if breathing resumes
- 6. Stay with the person — fentanyl outlasts naloxone, and breathing may stop again after 30–90 minutes
- 7. Do NOT leave after naloxone appears to work; re-narcotization is a documented risk with fentanyl[18]
What to tell the dispatcher: "Someone is not breathing / breathing very slowly. I think it's an opioid overdose. I've given naloxone." Provide the address, the number of people affected, and any other substances involved if known. Good Samaritan laws in most US states and Canadian provinces protect people who call for help during an overdose from drug possession charges.
Reversal agents: Naloxone (Narcan) is the standard reversal agent. Fentanyl overdoses may require higher or repeated doses compared to heroin overdoses.[29] Naloxone's effects last 30–90 minutes, shorter than fentanyl's — re-dosing or continuous monitoring is essential. Nalmefene (Opvee), a longer-acting antagonist, is an alternative where available.[30] If the chest is rigid and bag-valve-mask ventilation fails, this may be wooden chest syndrome — relay this to paramedics, as it may require muscle relaxants.
Legal Status[edit]
Fentanyl is controlled in virtually every country under the most restrictive schedules that still permit medical use.[1]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule II (Controlled Substances Act) | High abuse potential with accepted medical use; fentanyl-related substances classified Schedule I under temporary order (February 2018, extended through September 2025)[8] |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Maximum penalties for possession and supply[31] |
| Canada | Schedule I (CDSA, item 16) | Regulated under Narcotic Control Regulations; prescription required[32] |
| Australia | Schedule 8 (Controlled Drug) | Requires additional state/territory notification for prescribing[33] |
| Netherlands | Opium Law List I | Highest controlled category |
| EU member states | Nationally controlled per UN 1961 Convention | All member states control fentanyl; specific national schedule equivalents vary |
| International | Schedule I, UN Single Convention (1961) | Added 1964; obligates all signatory nations to control[1] |
Analog Scheduling
The proliferation of fentanyl analogs outpaced traditional substance-by-substance scheduling in most jurisdictions.[34] The US DEA responded with a class-wide Schedule I order for fentanyl-related substances in 2018, extended through September 2025.[8]
Legal status changes frequently and varies by jurisdiction. This information is for general reference only and is not legal advice.
Safety[edit]
- Acute toxicity
- Critical
- Chronic toxicity
- High
- Withdrawal
- Severe
- Tolerance buildup
- rapid
- Tolerance reset
- 14 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- morphine · heroin · oxycodone
Toxicity
Acute Toxicity
Fentanyl kills by suppressing breathing. μ-opioid agonism at brainstem respiratory centers reduces both the rate and depth of respiration,[6][21] and also blunts the body's normal alarm response to rising CO₂ levels. Death occurs through progressive oxygen deprivation.
The estimated lethal dose in opioid-naïve individuals is approximately 2 mg.safety citation needed Therapeutic serum concentrations for analgesia are 1–2 ng/mL; fatal cases typically show levels at or above 7 ng/mL.[1] The margin between a therapeutic and a lethal concentration can be as little as 3.5–7 times — critically narrow for a substance encountered in unregulated supply with unpredictable potency.
Wooden Chest Syndrome
Wooden chest syndrome (WCS) is fentanyl-induced muscle rigidity of the chest and abdomen that makes breathing mechanically impossible.[24][25] The chest wall becomes so stiff that bag-valve-mask ventilation fails. WCS may involve non-opioid receptor mechanisms,[9] which would explain why naloxone alone sometimes cannot reverse it.
Documented in the original clinical anesthesia literature,[2] WCS has re-emerged as a concern in illicit fentanyl overdoses where higher and more variable doses increase the risk.
Delayed Re-narcotization
Multiple or large doses cause fentanyl to accumulate in muscle and fat tissue. Hours later, this stored drug redistributes back into the bloodstream, producing secondary peaks in concentration and renewed respiratory depression.[20] This mechanism means that a person who appears to have recovered from an overdose can deteriorate hours later without additional drug exposure.
Xylazine Combination Toxicity
Xylazine, an animal tranquilizer increasingly found mixed with illicit fentanyl,[11] produces additive suppression of breathing and heart function.[26] Naloxone reverses the fentanyl component but has no effect on xylazine. Skin wounds (necrotic ulcers) at injection sites are a hallmark of xylazine-adulterated supply.
Epidemiology
Synthetic opioid-involved death rates in the United States increased 1,040% from 2013 to 2019.[3] Fentanyl contamination of non-opioid drug supplies, including methamphetamine and cocaine,[12] expands the at-risk population beyond people who intentionally use opioids.
Psychological Risks
Fentanyl's primary psychological risk is its addiction liability. Rapid brain entry (4.7–6.6 minutes to equilibrium[7]) and high receptor efficacy produce strong positive reinforcement that drives compulsive redosing. The combination of euphoria and anxiety suppression reinforces psychological dependence alongside the physical.
Chronic opioid use is associated with deficits in attention, memory, and executive function,citation needed though no study specific to fentanyl has characterized these effects.
Tolerance & Dependence
Tolerance develops through receptor-level changes: the body desensitizes and internalizes µ-opioid receptors in response to sustained activation,[5] while compensatory upregulation of cellular signaling establishes a new baseline that requires the drug's presence for normal function.[22]
Fentanyl may produce faster tolerance development than morphine.[27] Critically, evidence suggests tolerance to pain suppression develops faster than tolerance to respiratory depression[6] — meaning dose escalation to maintain analgesia progressively narrows the margin of safety for breathing. This asymmetry has not been confirmed in controlled human studies.safety citation needed
Cross-tolerance extends to all µ-opioid agonists: Morphine, heroin, oxycodone, hydrocodone, and methadone.
Physical dependence develops rapidly with regular use. Withdrawal produces dysphoria, muscle pain, tearing, runny nose, sweating, nausea, vomiting, diarrhea, and autonomic hyperactivity.citation needed Escalating self-administration and withdrawal behavior have been confirmed in animal models.[23]
Drug Interactions
Depressants: Benzodiazepines, alcohol, GHB/GBL, and other opioids (tramadol, Heroin) produce additive respiratory depression when combined with fentanyl. Benzodiazepine-opioid co-exposure is a well-documented risk factor for fatal overdose.
Gabapentinoids: gabapentin and pregabalin increase fentanyl's potency and decrease naloxone's ability to reverse fentanyl overdose in animal models.[28] This double-edged interaction — higher overdose risk with impaired reversal — is critically significant.
CYP3A4 inhibitors: Ketoconazole increases fentanyl exposure by 33%.[29] Ritonavir reduces fentanyl clearance and prolongs its effects.[30] Effects are more modest than for some other opioids but remain dangerous given fentanyl's narrow safety margin.
Xylazine: Additive depression of breathing and heart function; naloxone cannot reverse the xylazine component.[26]
Naloxone reversal considerations: Fentanyl overdoses likely require higher naloxone doses than heroin overdoses.[31] Intranasal naloxone 4 mg reverses fentanyl-induced respiratory depression but may show incomplete effectiveness in daily opioid users.[32] Nalmefene 1.5 mg IM achieves faster onset and longer duration of reversal compared to naloxone 4 mg intranasal.[33]
Buprenorphine reversed fentanyl-induced respiratory depression within 3.5 minutes in rats, comparable to naloxone,[34] supporting its investigation as an alternative reversal agent.
Contraindications
8 knownFentanyl is absolutely contraindicated in individuals with known allergy to fentanyl or other anilidopiperidine opioids, severe breathing difficulties (in unmonitored settings), and bowel obstruction.
Liver impairment reduces fentanyl clearance because the drug depends on liver blood flow for elimination.[19] Concurrent CYP3A4 inhibitors require dose reduction.
Concurrent use of benzodiazepines, alcohol, or other depressants constitutes a strong relative contraindication due to additive respiratory depression. Gabapentinoid co-use warrants specific caution given both enhanced fentanyl potency and impaired naloxone reversal.[28]
Elderly patients (half-life up to 15 hours[20]) and those with kidney impairment require dose adjustment.
Harm Reduction[edit]
Forms & Identification
The core challenge with illicit fentanyl is that potency is invisible. Pharmaceutical fentanyl comes in precisely dosed forms — patches, lozenges, injectable solutions — but illicitly manufactured fentanyl is distributed as powder, pressed pills, or liquid applied to blotter or nasal spray. Pressed pills often mimic the appearance of pharmaceutical oxycodone (M30 tablets) or benzodiazepines but contain wildly variable fentanyl concentrations, including fatal doses in a single pill.
Fentanyl test strips detect the presence of fentanyl in a sample but cannot determine concentration. A positive strip confirms the substance is present; a negative result does not guarantee safety, as distribution within a batch may be uneven. Testing every dose from a new batch is the minimum standard.
Guidelines
- Test every dose with fentanyl test strips before use
- Start with a fraction of the intended dose ("go low, go slow"), especially from a new batch or after any break in use — tolerance drops rapidly
- Never use alone; ensure someone present has naloxone and knows how to use it
- Have at least two doses of naloxone (Narcan) immediately accessible, not stored in another room
- Avoid mixing with benzodiazepines, alcohol, gabapentinoids, or other depressants — these combinations are the most common cause of fatal overdose
- If smoking or snorting, take a small test amount and wait before redosing
- If injecting, use slowly; rapid injection increases wooden chest syndrome risk
- After any tolerance break (days in hospital, jail, detox, or simply not using for 3+ days), assume your previous dose is now potentially fatal
Set & Setting
Fentanyl use carries acute lethal risk that makes environment and company safety-critical rather than preference-dependent. Never use alone — respiratory depression can progress from slowed breathing to apnea within minutes, and an unconscious person cannot self-administer naloxone. A sober companion with naloxone access and knowledge of rescue breathing is the single most effective risk reduction measure.
Avoid using in locations where emergency services cannot reach you. Do not use in water (baths, pools) where loss of consciousness means drowning.
Aftercare & integration. After an overdose reversal, the priority is medical monitoring. Naloxone wears off faster than fentanyl, and respiratory depression can return hours later.[20] Emergency department observation for at least 2–4 hours after the last naloxone dose is standard practice.
Naloxone reversal precipitates acute withdrawal in dependent individuals — intense dysphoria, pain, nausea, and agitation. This is medically expected and not dangerous, but the discomfort drives many people to leave medical care and use again immediately, creating a second overdose window. If you are supporting someone through reversal, understanding this dynamic helps you respond with patience rather than alarm.
For people not in crisis, regular fentanyl use produces cumulative physical and psychological toll. Sleep disruption, constipation, hormonal changes, and progressive sociability suppression are common. Honest self-assessment of escalating use patterns — needing more to feel the same effect, using to avoid withdrawal rather than for effect — is the first step toward seeking support.
Recovery & Support
Fentanyl dependence is treatable. Medications for opioid use disorder (MOUD) — buprenorphine (Suboxone, Sublocade) and methadone — are the most effective treatments available, reducing overdose death by 50% or more. These are not "replacing one drug with another"; they stabilize brain chemistry, eliminate withdrawal, and allow people to function.
Buprenorphine induction from fentanyl requires careful timing due to fentanyl's long tissue redistribution. Precipitated withdrawal (severe withdrawal triggered by starting buprenorphine too early) is a known risk with fentanyl specifically — low-dose ("microdosing") buprenorphine induction protocols have been developed to address this.
Methadone programs provide daily supervised dosing with gradual take-home privileges. For fentanyl dependence specifically, some individuals require higher methadone doses than were typical for heroin dependence.
Peer support resources include SMART Recovery, Narcotics Anonymous, and harm reduction organizations that offer low-barrier support regardless of whether someone is ready to stop using. The National Drug Helpline (1-844-289-0879) and SAMHSA Helpline (1-800-662-4357) provide free referrals.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Slow or stopped breathing, blue or gray lips and fingertips, gurgling or snoring sounds from an unconscious person, pinpoint pupils with unresponsiveness, rigid chest or abdomen (wooden chest syndrome). An opioid overdose can look like someone "nodding off" — the difference is that they cannot be woken by loud voice or sternal rub.
Immediate steps:
- 1. Call emergency services immediately
- 2. Administer naloxone: intranasal (4 mg spray in one nostril) or intramuscular injection
- 3. If no response after 2–3 minutes, administer a second dose of naloxone
- 4. Begin rescue breathing if the person is not breathing: tilt head back, lift chin, give one breath every 5 seconds
- 5. Place in recovery position (on their side) if breathing resumes
- 6. Stay with the person — fentanyl outlasts naloxone, and breathing may stop again after 30–90 minutes
- 7. Do NOT leave after naloxone appears to work; re-narcotization is a documented risk with fentanyl[20]
What to tell the dispatcher: "Someone is not breathing / breathing very slowly. I think it's an opioid overdose. I've given naloxone." Provide the address, the number of people affected, and any other substances involved if known. Good Samaritan laws in most US states and Canadian provinces protect people who call for help during an overdose from drug possession charges.
Reversal agents: Naloxone (Narcan) is the standard reversal agent. Fentanyl overdoses may require higher or repeated doses compared to heroin overdoses.[31] Naloxone's effects last 30–90 minutes, shorter than fentanyl's — re-dosing or continuous monitoring is essential. Nalmefene (Opvee), a longer-acting antagonist, is an alternative where available.[33] If the chest is rigid and bag-valve-mask ventilation fails, this may be wooden chest syndrome — relay this to paramedics, as it may require muscle relaxants.
Legal Status[edit]
Fentanyl is a controlled substance in virtually all jurisdictions worldwide, classified under the most restrictive schedules that still permit medical use. Internationally, fentanyl was added to Schedule I of the UN Single Convention on Narcotic Drugs (1961) in 1964.[1] All signatory nations are obligated to control its manufacture, distribution, and use.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule II (Controlled Substances Act) | High abuse potential with accepted medical use; fentanyl-related substances classified Schedule I under temporary order (February 2018, extended through September 2025)[8] |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Maximum penalties for possession and supply[35] |
| Canada | Schedule I (CDSA, item 16) | Regulated under Narcotic Control Regulations; prescription required[36] |
| Australia | Schedule 8 (Controlled Drug) | Requires additional state/territory notification for prescribing[37] |
| Netherlands | Opium Law List I | Highest controlled category |
| EU member states | Nationally controlled per UN 1961 Convention | All member states control fentanyl; specific national schedule equivalents vary |
| International | Schedule I, UN Single Convention (1961) | Added 1964; obligates all signatory nations to control[1] |
Analog Scheduling
The proliferation of illicitly manufactured fentanyl analogs outpaced traditional substance-by-substance scheduling in most jurisdictions.[38] The US DEA responded with a temporary class-wide Schedule I order for fentanyl-related substances as a structural class in February 2018, extended multiple times through September 2025.[8] Several other jurisdictions have adopted similar structural-class approaches to control emerging analogs before they can be individually identified and scheduled.
Frequently asked questions
What is Fentanyl?
Fentanyl is a synthetic anilidopiperidine opioid and full μ-opioid receptor agonist, 80–100× more potent than morphine. Synthesized in 1960 by Paul Janssen, it is used clinically in anesthesia and pain management across multiple routes of administration.
How long does Fentanyl last?
Total duration by route of administration — Sublingual: 1 – 4 hours; Insufflated: 1 – 4 hours; Transdermal: 48 – 72 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for Fentanyl?
Psychedex publishes a dosage table for Fentanyl on this page covering these routes of administration: sublingual, insufflated, transdermal, intravenous. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with Fentanyl?
The highest-severity documented interactions for Fentanyl: Benzodiazepines, Barbiturates (Lethal), GHB, Baclofen (Lethal), GHB, GBL (Lethal), Local anesthetics (Lethal), Alpha-2 adrenergic receptor antagonist (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is Fentanyl addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for Fentanyl: tolerance builds rapid; full reset takes 14 days; cross-tolerance develops with morphine, heroin, oxycodone, hydrocodone, methadone, codeine, hydromorphone, oxymorphone, buprenorphine. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1]
- [2] ^abcdStanley TH (1992) The history and development of the fentanyl series — Journal of Pain and Symptom Management doi:10.1016/0885-3924(92)90047-l
- [3] ^abcMattson CL, Tanz LJ, Quinn K, Kariisa M, Patel P (2021) Trends and Geographic Patterns in Drug and Synthetic Opioid Overdose Deaths - United States, 2013-2019 — MMWR Morbidity and Mortality Weekly Report doi:10.15585/mmwr.mm7006a4
- [4] ^Baylon GJ, Kaplan HL, Somer G, Busto UE, Sellers EM (2000) Comparative abuse liability of intravenously administered remifentanil and fentanyl — Journal of Clinical Psychopharmacology PMID:11106130
- [5] ^abHurle MA (2001) Changes in the expression of G protein-coupled receptor kinases and beta-arrestin 2 in rat brain during opioid tolerance and supersensitivity — Journal of Neurochemistry PMID:11299311
- [6]
references
- [1]
- [2]
- [3] ^abcMattson CL, Tanz LJ, Quinn K, Kariisa M, Patel P (2021) Trends and Geographic Patterns in Drug and Synthetic Opioid Overdose Deaths - United States, 2013-2019 — MMWR Morbidity and Mortality Weekly Report doi:10.15585/mmwr.mm7006a4
- [4] ^Baylon GJ, Kaplan HL, Somer G, Busto UE, Sellers EM (2000) Comparative abuse liability of intravenously administered remifentanil and fentanyl — Journal of Clinical Psychopharmacology PMID:11106130
- [5] ^abHurle MA (2001) Changes in the expression of G protein-coupled receptor kinases and beta-arrestin 2 in rat brain during opioid tolerance and supersensitivity — Journal of Neurochemistry PMID:11299311
- [6]